cyclophosphamide,ciltacabtagene autoleucel,lenalidomide,elotuzumab,ixazomib,idecabtagene vicleucel,panobinostat,venetoclax,pomalidomide,carfilzomib
secura bio,aveo oncology,amgen,lightchain biosciences,takeda,janssen,roche,bms,2seventy bio,abbvie,legend biotech
['ixazomib', 'carfilzomib', 'mmsm', 'elotuzumab', 'lenalidomide', 'venetoclax', 'bortezomib', 'pomalidomide', 'fil,veral,12', 'cyclophosphamide', 'ciltacabtagene autoleucel', ' lena', 'borte', 'idecabtagene', 'panobinostat', 'light chain', 'aveo']
congress l #ash22 from presents the latest findings from a retrospective, single-centre analysis of patients with rrmm progressing after car-t treatment. data from 78 patients identified a 2-year pfs of 34.6% and 2-year os of 13 months #mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma